Royalty Pharma Plc annual shares outstanding for fiscal TTM was 560 million shares, an increase of 0.0% from 560 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Shares Outstanding (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (M) | 560M | 560M | 594M | 603M | 565M | 415M | 375M | 354M | 354M | 354M | 607M | 607M | 354M | 354M | 354M | 354M | 354M | 354M | 354M | 354M | 354M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Shares Outstanding (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (M) | 560M | 560M | 560M | 562M | 578M | 589M | 593M | 597M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More RPRX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow
All RPRX financial statements → Interactive RPRX charts →
About TickerBase · Data methodology & sources